Navigation Links
Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
Date:10/22/2013

CAMBRIDGE, Mass., Oct. 22, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today provided a corporate update and reported financial results for the quarter ended September 30, 2013.

"2013 has been an important year for Epizyme as we translate the science of epigenetics into personalized therapeutics," said Robert Gould, Ph.D., chief executive officer. "We currently have two ongoing clinical programs, which to our knowledge are the only histone methyltransferase (HMT) inhibitor programs to have entered human clinical development. EPZ-5676, an inhibitor of the HMT DOT1L, is being developed as a treatment for patients with acute leukemias with rearrangements of the MLL gene (MLL-r). The dose escalation stage of the Phase 1 study of EPZ-5676 is proceeding and no dose-limiting toxicities have been observed to date. We have been highly encouraged by the tolerability thus far and believe this represents a significant step forward for this first-in-class epigenetic program and for the entire field. We anticipate completion of this stage by the end of the year. In the fourth quarter of 2013, we will share top-line dose escalation data and, based on data from the dose escalation stage, plan to initiate an expansion cohort stage that will be limited to patients with MLL-r. This expansion cohort is expected to provide an initial assessment of therapeutic effect in this population in 2014."

Dr. Gould continued, "In addition, for EPZ-6438, an inhibitor of the HMT EZH2 being developed as a treatment for non-Hodgkin lymphoma patients with oncogenic point mutations in EZH2, Epizyme, with our partner Eisai, initiated a Phase 1/2 clinical trial in June 2013. T
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
2. New Resource Provides Herb Industry With Sources of Quality Specifications
3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
7. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
8. Insmed Incorporated Provides Corporate Update
9. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Inc. (Nasdaq: TWTI) today announced it delivered a total ... Japan for use in various large scale genotyping projects. , ... its Invader SNP assays to Dr. Yusuke Nakamura, group director ... director of the Genome Center at the University of ...
... Note: This is the first of a multi-part interview ... , managing director of the Wisconsin Alumni Research Foundation ... WARF initiative called Whats in it for Wisconsin Business. This ... foundation more accessible to companies throughout the state, as well ...
... Marie the other day: Thats it! This makes the third time Ive ... see my job go away. Im done Im going out on ... the corporate world in droves, to strike out on their own (and ... dozen people what a great consultant you would make. Maybe you would! ...
Cached Biology Technology:WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 2WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 3WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 4Is Now the Time to Go on Your Own? 2Is Now the Time to Go on Your Own? 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... formed from complex biochemical reactions within the human body, ... Cheng, associate professor in the Artie McFerrin Department of ... a model that simulates how these wave patterns are ... issue of the journal "Physical Review E," ...
... are 1/100,000 the width of a human hair to deliver ... may sound like something out of a science fiction movie, ... near future. Carbon nanotubes, cylindrically shaped carbon ... potential applications in a variety of fields, such as biomedical ...
... , This release is available in German ... accumulation and detoxification of arsenic in plant cells have been ... involving laboratories in Switzerland, South Korea and the United States, ... Competence in Research (NCCR) Plant Survival. The results presented are ...
Cached Biology News:Research links damaged organs to change in biochemical wave patterns 2Nanotechnology: A dead end for plant cells? 2Using plants against soils contaminated with arsenic 2
... of the popular precision current source, ... of neural transport tracers such as ... acids into neural tissue, is now ... be used to make small lesions, ...
... The thermostable dUTPase(pyrococcus fruriosus) maximizes the ... DNA polymerases). It removes contaminating ... dNTP solutions. The presence of ... reaction can prevent dUTP misincorporation by ...
... The FLUOstar OPTIMA is a fully ... for life science labs in academia ... different measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
... kit measures mitochondria intactness and detects ... potential. Features and Benefits: ... staining isolated mitochondria and for assaying ... the reagents required for the detection ...
Biology Products: